The effect of G-CSF use on hospital length of stay after an allogeneic hematopoietic cell transplantation: a retrospective multicenter cohort study

Gemlyn George, MBBS\textsuperscript{1}, Andrew St Martin, MS\textsuperscript{2}, Saurabh Chhabra, MD\textsuperscript{1,2}, Mary Eapen, MBBS, MS\textsuperscript{1,2}

\textsuperscript{1}Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

\textsuperscript{2}Center for International Blood and Bone Marrow Transplant Registry, Department of Medicine, Milwaukee, WI

Abstract

Granulocyte colony stimulating factor (G-CSF) is administered after allogeneic hematopoietic cell transplantation (HCT) to aid with neutrophil recovery. We compared the effect of empiric G-CSF administration on duration of index inpatient hospitalization stay after HCT for patients aged $\geq$18 years with hematologic malignancy. G-CSF was considered empiric if administered between day $-3$ to day +6 in relation to infusion of the graft. We studied 3562 transplants (N=1487 HLA-matched sibling and N=2075 HLA-matched unrelated donor) between 2007 to 2016. Three hundred and thirteen (21\%) recipients of HLA-matched sibling and 417 (20\%) recipients of HLA-matched unrelated donor HCT received empiric G-CSF. The effect of G-CSF on index hospitalization stay was examined in general linear models (GLM) with adjustment for other patient, disease and transplant characteristics and acute graft-versus-host disease and infection post-transplant. Length of index hospitalization by treatment group did not differ for HLA-matched sibling HCT but was shorter with G-CSF (15 vs. 19 days, p<0.001) for HLA-matched unrelated donor HCT. GLM models confirmed shorter hospitalization with use of G-CSF for HLA-matched unrelated donor HCT (p=0.01). G-CSF was not associated with early survival for either donor type. There is no benefit or disadvantage of giving G-CSF to promote neutrophil recovery.

Keywords

G-CSF; Allogeneic hematopoietic cell transplant; length of stay
INTRODUCTION

Hematopoietic growth factors such as granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) have been shown to promote faster neutrophil recovery after hematopoietic cell transplantation (HCT) [1,2]. An earlier study from the Center for International Blood and Marrow Transplant Research (CIBMTR) in adults with leukemia observed shortening of the neutropenic period post transplantation [3]. In that study, G-CSF was administered within 7 days of infusion of the graft and duration of hospitalization was similar between groups receiving G-CSF for both peripheral blood and bone marrow grafts) [3]. The study also did not observe differences in early treatment related mortality, acute and chronic graft-versus-host disease (GVHD), relapse, leukemia free or overall survival [3]. Results of two meta analyses failed to demonstrate an effect of empiric G-CSF use on treatment related mortality and GVHD [4,5]. One of the meta-analysis also compared the effect of G-CSF on duration of hospitalization and found a three-day reduction in hospitalization in the group that received G-CSF [5].

Since the publication of the above-mentioned reports there have been several changes in the field of HCT. Increasing numbers of patients over 60 years are undergoing HCT, there has been an increase in the use of reduced intensity and non-myeloablative conditioning regimens to extend transplantation to those with co-morbidities, an increase in 8/8 HLA matched unrelated donor transplants and the near universal use of peripheral blood graft. In the current era of escalating healthcare costs, resource utilization is a priority for transplant centers [6]. A report from the Agency for the Healthcare Research and Quality (AHRQ) noted that HCT ranked among the top 10 procedures with the most rapid increase in hospital costs in the US [7]. The median cost of an HCT (based on data from 2007-2009) in the first 100 days was $203,026 (IQR, $141,742–316,426) with more than 75% of costs attributable to inpatient stay[8]. As G-CSF use promotes faster neutrophil recovery, this could potentially be used as a tool to reduce duration of inpatient stay and thus healthcare costs. Thus, the current analysis sought to study the effect of empiric G-CSF on the duration of inpatient hospitalization in the first 100 days after HLA-matched sibling and 8/8 HLA matched unrelated peripheral blood transplants for acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS).

METHODS

Patients

The CIBMTR is a group of over 300 transplant centers worldwide that contribute data prospectively on consecutive transplants performed at each individual center and patients are followed longitudinally until death or lost to follow-up. Included are patients aged 18 year and older with AML, ALL, or MDS, received peripheral blood grafts and planned to be admitted to the hospital for transplantation. Transplants occurred between 2007 and 2016 in the United States. Patients received grafts from an HLA-matched sibling or unrelated donor, matched at the allele-level at HLA-A, -B, -C, -DRB1. G-CSF administration was considered empiric if date of onset was between day −3 to day +6 in relation to the date of infusion of the graft. Forty-two patients admitted for transplantation died prior to discharge and were excluded. Recipients of out-patient transplants were excluded. Other exclusions included
transplantation with CD34 selected graft, \textit{ex vivo} and \textit{in vivo} T-cell depletion, HLA-mismatched relative or unrelated donors, GM-CSF for neutrophil recovery and post-transplant cyclophosphamide for graft-versus-host disease (GVHD) prophylaxis. Patients provided written informed consent for research. The Institutional Review Board of the National Marrow Donor Program approved this study.

**Outcomes**

The primary outcome was duration of index inpatient hospitalization for transplantation. The duration was calculated from date of transplant to date of first discharge from hospital. Neutrophil recovery was defined as achieving an absolute neutrophil count (ANC) of $\geq 0.5 \times 10^9$/L for 3 consecutive days. Acute grade II-IV GVHD were based on reports from each transplant center and using standard criteria [9]. Death from any cause was considered an event and surviving patients were censored at last follow-up.

**Statistical analysis**

Patient, disease, and transplantation characteristics of those that received empiric G-CSF and those who did not were compared using the Chi-square test for categoric variables and the Wilcoxon test for continuous variables. The probability for overall survival were estimated using the Kaplan-Meier estimator [10]. The day-28 incidence of neutrophil recovery was calculated using the cumulative incidence estimator to accommodate competing risks [11]. As donor type is a significant predictor for overall survival, analyses on transplant outcomes were studied separately for HLA-matched sibling and HLA-matched unrelated donor transplants.

We used a multivariable generalized linear model (GLM) with duration of index inpatient hospital days as the outcome variable to study the effect of empiric G-CSF, 3-months after transplantation [12]. Variables tested included empiric G-CSF administration, age, sex, race, ethnicity, performance status, hematopoietic cell transplantation-comorbidity index (HCT-CI), cytomegalovirus serostatus, interval from diagnosis to transplant, disease-risk index (DRI; composite of disease, disease status and cytogenetic risk), conditioning regimen intensity, GVHD prophylaxis, transplant period, grade II-IV acute GVHD and systemic bacterial, viral and fungal infections. A Cox regression model was built to study the effect of empiric G-CSF administration on 3-month survival, adjusted characteristics described above [13]. A stepwise model building approach was adopted and variables that attained a p-value <0.05 (two-sided) were retained in the final model with the exception of G-CSF administration, which was held in all steps of model building regardless of level of significance. All analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC).

**RESULTS**

**Patient, disease and transplant characteristics**

Of the 1487 patients who received their graft from their HLA matched sibling, 21\% (313 of 1487) received empiric G-CSF (Table 1). The characteristics of those who received and did not receive G-CSF were similar except those who received G-CSF were more likely to be male, non-Caucasians, receive reduced intensity conditioning regimens and calcineurin...
inhibitor with mycophenolate for GVHD prophylaxis. Of the 2075 patients who their graft from an HLA matched unrelated donors 20% (417 of 2075) received empiric G-CSF (Table 2). Characteristics of the treatment groups were similar except patients who received G-CSF were more likely to have performance scores less than 90, more likely to receive reduced intensity conditioning regimens and less likely to receive G-CSF in the period 2012 - 2016.

**Index inpatient hospitalization**

We did not observe a difference in length of index hospitalization between those who received and did not receive G-CSF after HLA-matched sibling. The median length of hospitalization was 17 days (interquartile range [IQR] 14-21) in those who received G-CSF and 18 days (IQR 15-22) in those who did not receive G-CSF (p=0.06). Among recipients of HLA-matched unrelated donor transplant, index length of hospitalization was shorter for those who received G-CSF (median 15 days [IQR 12-21]) compared to those who did not receive G-CSF (median 19 days [IQR 15-22]), p<0.001. Multivariate analysis confirmed shorter index hospitalization for those who received G-CSF compared to those who did not receive G-CSF after HLA-matched unrelated donor transplant (Table 3).

**Neutrophil recovery and overall survival**

Among recipients of HLA-matched sibling transplants, the median time to neutrophil recovery was faster at 12 days (10-14) for patients who received G-CSF compared to 15 days (IQR, 13 – 17) for those who did not receive G-CSF (p<0.001). Nevertheless, by day-28, incidence of neutrophil recovery did not differ between treatment groups, 98% (95% confidence interval [CI], 96-99) and 98% (95% CI, 98-99), with and without G-CSF (p=0.32). The corresponding 3-month probability of survival was 92% (95% CI 89-95) and 94% (95% CI 93-96), p=0.17. Multivariate analysis confirmed absence of a difference in overall survival by treatment group (Table 4).

Among recipients of HLA-matched unrelated donor transplants, the median time to neutrophil recovery was also faster at 11 days (IQR, 10- 13) for patients who received G-CSF compared to 15 days (IQR, 13-17) for those who did not receive G-CSF (p<0.001). The day-28, incidence of neutrophil recovery did not differ between treatment groups, 97% (95% CI, 95-98) and 98% (95% CI, 97-98), with and without G-CSF (p=0.38). The corresponding 3-month probability of survival was 88% (95% CI 85-91) and 91% (95% CI 90-92), p=0.09. Multivariate analysis confirmed absence of a difference in overall survival by treatment group (Table 4).

**DISCUSSION**

The role of G-CSF has been extensively evaluated in allogeneic transplantation with some studies suggesting higher risks for acute GVHD and treatment related mortality after bone marrow transplantation [14,15]. However, none of the studies have shown an advantage with G-CSF other than faster neutrophil recovery which has not resulted in better survival [3,5]. Correspondingly, guidelines from the American Society of Clinical Oncology do not have a strong recommendation for G-CSF use after an allogeneic transplantation other than acknowledge faster neutrophil recovery [16]. Yet data reported to the CIBMTR, an
observational registry for HCTs suggest G-CSF is used empirically for ~20% of HLA-matched related and HLA-matched unrelated donor transplantations in the US for adults with acute leukemia and MDS. This prompted the current analysis with its focus on index length of hospitalization. The period of neutropenia was shorter in patients who received G-CSF after HLA-matched sibling and HLA-matched unrelated donor transplantation. However, index length of hospitalization was shorter for recipients of HLA-matched unrelated donor transplantations but not HLA-matched sibling transplantations. Thus, in the setting of HLA-matched sibling transplantation these data do not support empiric G-CSF for adults with acute leukemia and MDS. The findings in the setting of HLA-unrelated donor transplantation may be relevant in the current economic situation knowing time spent as an inpatient is a major driver of early costs associated with transplantation. Others have shown early transplantation cost account for 75-90% of total cost associated with transplantation [17-19]. The findings from our generalized linear model adjusted for other patient, disease and transplant characteristics associated with unrelated donor transplantation showed a reduction in index hospitalization by 1.7 days. Drug purchasing contracts vary between hospitals and the monetary advantage from an approximate reduction in 2 days of hospitalization must be considered in the context of G-CSF administration over a 2-3 week period. As the data in the current analysis was obtained from a registry we did not have access to costs associated with the transplantations and acknowledge our limitation.

There are several other measures that have been instituted to lower cost associated with transplantation including outpatient transplants [6,20,21]. In fact, one study that examined costs associated with transplantation observed a substantial increase in cost with readmissions within the first 100 days after HCT [21]. In our population, approximately 65% of recipients of HLA-matched sibling and HLA-matched unrelated donor transplantations was readmitted within the first 100 days but the proportion of readmissions did not differ by whether G-CSF was given. In a multivariate analysis, considering the length of hospitalization within the first 100 days, we did not observe a significant difference between those who received and did not receive empiric G-CSF after HLA-matched sibling (coefficient=0.93, p=0.26) and HLA-matched unrelated donor (coefficient=0.82, p=0.28) transplants. We did not observe differences in survival and our findings are consistent with all reports on G-CSF administration [1-5]. We did not observe differences in grade II-IV acute GVHD by G-CSF administration after HLA-matched sibling and HLA-matched unrelated donor transplantation (data not shown). These findings are consistent with that of others.

There are several limitations. Our study is an analysis of an existing cohort rather than a prospective design which is considered the “ideal” when evaluating treatments. A prospective study in which patients are randomly assigned empiric G-CSF or not is unlikely considering the prohibitive costs associated with prospective studies. We do not know why G-CSF was administered and may reflect physician preference, institutional practice or an unknown or unmeasured factor. Our models adjusted for known characteristics and confirmed a reduction in index hospitalization by 1.7 days in recipients of HLA-matched unrelated donor transplantation. However, considering over 60% of patients required at least one re-admission we do not know whether early discharge (no greater than 2 days) offer a monetary advantage. Further, we only considered G-CSF and not GM-CSF. In the meta-
analysis by Dekker and colleagues, infections were substantially lower in patients who received GM-CSF but not G-CSF [5]. We also excluded umbilical cord blood and haploidentical donor transplantations and use of post-transplant cyclophosphamide for GVHD prophylaxis.

In summary, these data do not support use of empiric G-CSF for HLA-matched sibling transplantation for adults with acute leukemia and MDS. For HLA-matched unrelated donor transplantation we observed shorter index hospitalization but without differences in readmission within the first 100 days or overall survival. This observation merits further investigation which is beyond the scope of this analysis or the available data in the registry.

Acknowledgments

Funding: The Center for International Blood and Marrow Transplant Research is supported primarily by Public Health Service Grant/Cooperative Agreement U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); contract HHSN250201200016C with Health Resources and Services Administration (HRSA/DHHS); grants N00014-15-1-0848 and N00014-16-1-2020 from the Office of Naval Research. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration or any other agency of the U.S. Government.

REFERENCES:

1. Przepiorka D, Smith TL, Folloder J, et al. Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors. Blood. 2001; 97: 3405–3410. [PubMed: 11369630]
2. Bishop MR, Tarantolo SR, Geller RB, et al. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood. 2000; 96: 80–85. [PubMed: 10891434]
3. Khoury HI, Loberiza FR, Ringdén O, et al. Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood. 2006; 107: 1712–1716. [PubMed: 16239431]
4. Ho VT, Mirza NQ, del Junco Dd D, Okamura T, Przepiorka D. The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis. Bone Marrow Transplant. 2003; 32: 771–775. [PubMed: 14520420]
5. Dekker A, Bulley S, Beyene J, Dupuis LL, Doyle JJ, Sung L. Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol. 2006; 24: 5207–5215. [PubMed: 17114653]
6. Khera N, Zeliadt SB, Lee SJ. Economics of hematopoietic cell transplantation. Blood. 2012; 120: 1545–1551 [PubMed: 22700725]
7. Stranges E, Russo CA, Friedman B. Procedures with the most rapidly increasing hospital costs, 2004–2007: statistical brief# 82, Healthc. Cost Util. Proj. Stat. Briefs. Rockv (2006).
8. Majhail NS, Mau LW, Denzen EM, Arneson TJ. Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large national private claims database. Bone Marrow Transplant. 2013; 48: 294–300. [PubMed: 22773126]
9. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825–828. [PubMed: 7581076]
10. Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. J Am Stat Assoc. 1958; 53: 457–481.
11. Fine JP, Gray RJ. A proportional hazards model for the sub distribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509.
12. Nelder JA, Wedderburn RWM. Generalized linear models. J.R. Stat. Soc. Ser. A 1972;135(3):370–384.
13. Cox DR. Regression Models and Life-Tables. J. R. Stat. Soc. Ser. B 1972; 34: 187–220.
14. Rembrinker M M, Naseh N N, Aschan J J, et al. G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV. Bone Marrow Transplant. 2003; 32: 217–223. [PubMed: 12838288]
15. Ringdén O, Labopin M, Gorin NC, et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood. J Clin Oncol. 2004; 22: 416–423. [PubMed: 14691124]
16. Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015; 33: 3199–3212. [PubMed: 26169616]
17. Blommestein HM, Verelst SGR, Huijgens PC, et al. Real-world costs of autologous and allogeneic stem cell transplantations for haematological diseases: a multicentre study. Ann Hematol. 2012; 91: 1945–1952. [PubMed: 22864761]
18. Saito AM, Cutler C, Zahrieh D, et al. Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. Biol Blood Marrow Transplant. 2008; 14: 197–207. [PubMed: 18215780]
19. Preussler JM, Denzen EM, Majhail NS. Costs and cost-effectiveness of hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012; 18: 1620–1628. [PubMed: 22484549]
20. Granot N, Storer BE, Cooper JP, Flowers ME, Sandmaier BM, Storb R. Allogeneic Hematopoietic Cell Transplantation in the Outpatient Setting. Biol Blood Marrow Transplant. 2019; 25: 2152–2159. [PubMed: 31255743]
21. Guru Murthy GS, Hari PN, Szabo A, et al. Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. Biol. Blood Marrow Transplant 2019; 25: 827–833. [PubMed: 30572109]
# Highlights

1. Empiric G-CSF shortens length of in-patient stay after HLA-matched unrelated donor transplant
2. Empiric G-CSF does not shorten length of in-patient stay after HLA-matched sibling transplant
3. Empiric G-CSF is not associated with early survival
Table 1.
HLA-matched sibling transplant: patient, disease and transplant characteristics

| Characteristic                              | No G-CSF | G-CSF | P value |
|---------------------------------------------|----------|-------|---------|
| No. of patients                             | 1174     | 313   |         |
| Age, years                                  |          |       |         |
| 18- 30                                      | 113 (10%)| 26 (8%)| 0.47    |
| 31- 40                                      | 127 (11%)| 25 (8%)|         |
| 41- 50                                      | 240 (20%)| 61 (19%)|         |
| 51- 60                                      | 381 (32%)| 118 (38%)|         |
| 61- 70                                      | 283 (24%)| 75 (24%)|         |
| > 70                                        | 30 (3%)  | 8 (3%) |         |
| Gender                                      |          |       |         |
| Male                                        | 649 (55%)| 193 (62%)| 0.04   |
| Female                                      | 525 (45%)| 120 (38%)|         |
| Race                                        |          |       |         |
| Caucasian                                   | 1023 (87%)| 252 (81%)| < 0.001|
| African American                            | 48 (4%)  | 29 (9%) |         |
| Asian and other races                       | 103 (9%) | 32 (10%)|         |
| Ethnicity                                   |          |       |         |
| Non-Hispanic                                | 1019 (87%)| 263 (84%)|         |
| Hispanic                                    | 155 (13%)| 50 (16%)|         |
| Performance score                           |          |       |         |
| 90-100                                      | 709 (60) | 177 (57%)| 0.25   |
| <90                                         | 465 (40) | 136 (43%)|         |
| Hematopoietic cell transplantation- comorbidity index |        |       |         |
| 0-2                                         | 680 (58%)| 176 (56%)| 0.59   |
| 3+                                          | 494 (42%)| 137 (44%)|         |
| Donor-recipient cytomegalovirus serostatus  |          |       |         |
| Positive / Positive                         | 478 (41%)| 120 (38%)| 0.86   |
| Positive / Negative                         | 156 (13%)| 42 (13%)|         |
| Negative / Positive                         | 292 (25%)| 84 (27%)|         |
| Negative / Negative                         | 248 (21%)| 67 (21%)|         |
| Disease                                     |          |       |         |
| Acute myeloid leukemia                      | 636 (54%)| 167 (53%)|         |
| Acute lymphoblastic leukemia                | 202 (17%)| 55 (18%)|         |
| Myelodysplastic syndrome                    | 336 (29%)| 91 (29%)|         |
| Disease risk index                          |          |       |         |
| Low                                         | 58 (5%)  | 12 (4%) | 0.96   |
| Intermediate                                | 712 (61%)| 190 (61%)|         |
| High and Very High                          | 404 (34%)| 111 (35%)|         |
| Time to transplant from diagnosis          |          |       |         |
| Less than one year                          | 886 (75%)| 229 (73%)| 0.40   |
| Characteristic                                      | No G-CSF | G-CSF | P value |
|----------------------------------------------------|----------|-------|---------|
| More than one year                                 | 288 (25%) | 84 (27%) | <0.001  |
| Conditioning regimen intensity                     |          |       |         |
| Myeloablative, total body irradiation containing   | 369 (31%) | 73 (23%) |         |
| Myeloablative, non-total body irradiation containing | 406 (35%) | 112 (36%) |         |
| Reduced intensity, total body irradiation containing | 70 (6%)   | 44 (14%) |         |
| Reduced intensity, non-total body irradiation containing | 329 (28%) | 84 (27%) |         |
| GVHD prophylaxis                                   |          |       | < 0.001 |
| Calcineurin inhibitor + mycophenolate              | 250 (21%) | 95 (30%) |         |
| Calcineurin inhibitor + methotrexate               | 715 (61%) | 178 (57%) |         |
| Calcineurin inhibitor + other                      | 209 (18%) | 40 (13%) |         |
| Transplant period                                  |          |       | 0.37    |
| 2007-2011                                          | 537 (46%) | 152 (49%) |         |
| 2011-2016                                          | 637 (54%) | 161 (51%) |         |
| Median follow up in months (Min-Max)               | 62.8(3-125) | 70.9 (12-123) |         |
Table 2.
HLA-matched unrelated donor transplant: patient, disease and transplant characteristics

| Characteristic                          | No G-CSF | G-CSF | P value |
|----------------------------------------|----------|-------|---------|
| No. of patients                        | 1658     | 417   |         |
| Age, years                             |          |       | 0.28    |
| 18-30                                  | 168 (10%)| 31 (7%)|         |
| 31-40                                  | 161 (10%)| 36 (9%)|         |
| 41-50                                  | 258 (16%)| 57 (14%)|        |
| 51-60                                  | 408 (25%)| 104 (25%)|       |
| 61-70                                  | 544 (33%)| 158 (38%)|       |
| > 70                                   | 119 (7%) | 31 (7%)|         |
| Sex                                    |          |       | 0.25    |
| Male                                   | 958 (58%)| 254 (61%)|       |
| Female                                 | 700 (42%)| 163 (39%)|       |
| Race                                   |          |       | 0.78    |
| Caucasian                              | 1527 (92%)| 382 (92%)|       |
| African American                       | 45 (3%)  | 14 (3%)|         |
| Asian and other races                  | 86 (5%)  | 21 (5%)|         |
| Ethnicity                              |          |       | 0.36    |
| Non-Hispanic                           | 1555 (94%)| 386 (93%)|       |
| Hispanic                               | 103 (6%) | 31 (7%)|         |
| Performance score                      |          |       | 0.007   |
| 90-100                                 | 1003 (60%)| 205 (49%)|       |
| <90                                    | 655 (40%)| 212 (51%)|        |
| Hematopoietic cell transplantation- comorbidity index |          |       | 0.34    |
| 0-2                                    | 906 (55%)| 217 (52%)|       |
| 3+                                     | 752 (45%)| 200 (48%)|        |
| Donor-recipient cytomegalovirus serostatus |          |       | 0.07    |
| Positive / Positive                    | 411 (25%)| 94 (23%)|         |
| Positive / Negative                    | 179 (11%)| 59 (14%)|         |
| Negative / Positive                    | 577 (35%)| 126 (30%)|       |
| Negative / Negative                    | 491 (30%)| 138 (33%)|       |
| Disease                                |          |       | 0.92    |
| Acute myeloid leukemia                 | 854 (52%)| 212 (51%)|       |
| Acute lymphoblastic leukemia           | 209 (13%)| 51 (12%)|         |
| Myelodysplastic syndrome               | 595 (36%)| 154 (37%)|       |
| Disease risk index                     |          |       | 0.87    |
| Low                                    | 66 (4%)  | 15 (4%)|         |
| Intermediate                           | 932 (56%)| 231 (55%)|       |
| High and Very High                     | 660 (40%)| 171 (41%)|       |
| Time to transplant from diagnosis      |          |       | 0.64    |
| Less than one year                     | 1196 (72%)| 296 (71%)|       |
| Characteristic                                      | No G-CSF | G-CSF | P value |
|----------------------------------------------------|----------|-------|---------|
| More than one year                                 | 462 (28%)| 121 (29%)| <0.001 |
| Conditioning regimen intensity                     |          |       |         |
| Myeloablative, total body irradiation containing   | 335 (20%)| 60 (14%)|         |
| Myeloablative, non-total body irradiation containing| 565 (34%)| 122 (29%)|         |
| Reduced intensity, total body irradiation containing| 144 (9%)| 37 (9%)|         |
| Reduced intensity, non-total body irradiation containing| 614 (37%)| 198 (47%)|         |
| GVHD prophylaxis                                   |          |       | 0.25    |
| Calcineurin inhibitor + mycophenolate               | 421 (25%)| 115 (28%)|         |
| Calcineurin inhibitor + methotrexate                | 953 (57%)| 244 (59%)|         |
| Calcineurin inhibitor + other                       | 284 (17%)| 58 (14%)|         |
| Transplant period                                  |          |       | <0.001  |
| 2007-2011                                           | 590 (36%)| 195 (47%)|         |
| 2011-2016                                           | 1068 (64%)| 222 (53%)|         |
| Median follow up in months (Min-Max)               | 59.1 (3-125)| 63.2 (11-123)|     |
## Table 3.

Linear model (GLM) with coefficients showing differences in length of hospitalization during the index hospitalization.

| Matched Sibling Donor | Matched Unrelated Donor |
|-----------------------|-------------------------|
|                       | Coefficient | P value | Coefficient | P value |
| **G-CSF**             | 0.18         | 0.78    | −1.9        | 0.02    |
| Gender: Male          | 0.9          | 0.10    | 0.3         | 0.59    |
| Race: Caucasian       | −2.8         | 0.003   | −2.1        | 0.16    |
| Race: African American| −2.5         | 0.09    | −0.4        | 0.86    |
| Ethnicity: Hispanic (vs non-Hispanic) | 1.8 | 0.02 | 3.5 | 0.008 |
| Performance score <90 | 1.1          | 0.05    | 2.7         | <0.001  |
| HCT-comorbidity index ≥5 | 0.5    | 0.35 | 0.8 | 0.23 |
| CMV Positive/Negative | 1.3          | 0.12    | −0.2        | 0.83    |
| CMV Negative/Positive | 0.4          | 0.50    | −0.2        | 0.82    |
| **Disease: AML**      | −0.7         | 0.29    | −0.8        | 0.33    |
| **Disease: ALL**      | −0.8         | 0.44    | −0.7        | 0.60    |
| High/very high disease risk index | 2.2 | 0.10 | −0.2 | 0.86 |
| Intermediate disease risk index | 2.6 | 0.04 | −0.7 | 0.65 |
| Time to transplant from diagnosis (< 1 year) | −0.6 | 0.31 | −0.2 | 0.72 |
| Period of transplant 2007-2011 | 1.3 | 0.03 | 1.4 | 0.04 |
| TBI containing myeloablative regimen | 1.4 | 0.04 | 1.9 | 0.04 |
| TBI containing reduced intensity regimen | −2.0 | 0.10 | −1.9 | 0.17 |
| Non TBI containing reduced intensity regimen | 0 | 0.97 | −1.0 | 0.22 |
| Calcineurin inhibitor + Mycophenolate | −0.7 | 0.43 | −5.3 | <0.001 |
| Calcineurin inhibitor + methotrexate | −1.0 | 0.19 | −4.7 | <0.001 |
| Acute GVHD Grade 2-4 | 4.0          | <0.001  | 4.6         | <0.001  |
| Viral infection       | 0.1          | 0.82    | 0.6         | 0.34    |
| Bacterial infection   | 1.7          | 0.002   | 2.1         | 0.002   |
| Fungal infection      | 0            | 0.98    | 1.9         | 0.14    |

Baseline variables for the model (categorical variables):

- Gender: Female; Race: Asian and others; Ethnicity: Non-Hispanic; Performance score: 90-100; HCT-CI: 0-2; CMV status: Positive/Positive;
- Disease: MDS; Time from transplant to diagnosis: > 1 year; Period of transplant: 2012-2016;
- Conditioning regimen: Non TBI containing myeloablative regimen; GVHD Prophylaxis: calcineurin inhibitor + others

*Biol Blood Marrow Transplant. Author manuscript; available in PMC 2021 December 01.*
Table 4.
Cox proportional hazard model for overall survival.

| Characteristics          | Hazard ratio (95% CI) | P value |
|--------------------------|-----------------------|---------|
| **Matched Sibling Donor**|                       |         |
| G-CSF                    | 1.10 (0.94-1.30)      | 0.23    |
| Performance status       | 1.20 (1.04-1.39)      | 0.009   |
| HCT-CI (≥3)              | 1.37 (1.19-1.57)      | <0.001  |
| High and very high DRI   | 2.10 (1.42-3.09)      | <0.001  |
| GVHD (Grade 2-4)         | 1.72 (1.43-2.05)      | <0.001  |
| Bacterial infection      | 1.33 (1.16-1.54)      | <0.001  |
| Viral infection          | 1.18 (1.16-1.37)      | 0.028   |
| **Matched unrelated donor** |                     |         |
| G-CSF                    | 1.06 (0.92-1.23)      | 0.35    |
| Performance status       | 1.27 (1.13-1.43)      | <0.001  |
| HCT-CI (≥3)              | 1.37 (1.22-1.54)      | <0.001  |
| High and very high DRI   | 2.58 (1.76-3.78)      | <0.001  |
| Intermediate DRI         | 1.66 (1.13-2.43)      | 0.009   |
| GVHD (Grade 2-4)         | 2.04 (1.77-2.36)      | <0.001  |
| Bacterial infection      | 1.17 (1.04-1.32)      | 0.007   |
| Fungal infection         | 1.60 (1.30-1.96)      | <0.001  |